The Embargo Has Ended for the ASCO 2019 Presscast

The embargo for the 2019 pre-conference presscast for the American Society of Clinical Oncology (ASCO) has ended.

Discussants described five studies to be presented at this year's meeting.

I have been admitted, and I have made travel arrangements. I will be at the meeting, and I can cover it for you.

https://meetings.asco.org/am/program

Abstract 520: Low-fat dietary pattern and long-term breast cancer incidence and mortality: The Women’s Health Initiative randomized clinical trial (Chlebowski, Aragaki, Anderson, et al)

Abstract 10011: Identification of targetable molecular alterations in the NCI -COG Pediatric MATCH trial. (Parsons, Janeway, Patton, et al).

Abstract 10009: Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors. (Robinson, Gajjar, Gauvain, et al).

Abstract 4006: Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. (Hall, Swinson, Waters, et al).

E3A06: Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High Risk Smoldering Multiple Myeloma (Lonial, Jacobus, Fonseca, et al)